更新于：2024-06-24
Urapidil
乌拉地尔
更新于：2024-06-24
概要
基本信息
结构
分子式C20H29N5O3 |
InChIKeyICMGLRUYEQNHPF-UHFFFAOYSA-N |
CAS号34661-75-1 |
关联
15
项与 乌拉地尔 相关的临床试验乌拉地尔缓释胶囊（30mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial
Effects of Different Kinds of Antihypertensive Drugs on Dynamic Hemodynamic Changing of During Laparoscopic Gastrectomy and Laparotomy
100 项与 乌拉地尔 相关的临床结果
登录后查看更多信息
100 项与 乌拉地尔 相关的转化医学
登录后查看更多信息
100 项与 乌拉地尔 相关的专利（医药）
登录后查看更多信息
649
项与 乌拉地尔 相关的文献（医药）2023-09-20Journal of healthcare engineering
Retracted: Comparison of Clinical Efficacy of Sodium Nitroprusside and Urapidil in the Treatment of Acute Hypertensive Cerebral Hemorrhage
作者: Healthcare Engineering, Journal Of
[This retracts the article DOI: 10.1155/2022/2209070.].
2023-09-01Clinical pharmacology and therapeutics
Hypoxia Associated With Dihydropyridine Calcium Channel Inhibitors: A Pharmacovigilance Study in VigiBase
Article
作者: Fischer, Marc-Olivier ; Descamps, Richard ; Dolladille, Charles ; Decros, Jean Baptiste ; Chrétien, Basile ; Alexandre, Joachim ; Suard, Florimond
Due to their negative effects on hypoxic pulmonary vasoconstriction, dihydropyridine calcium channel inhibitors (DCCIs) can lead to hypoxia in patients with a pulmonary shunt. To date, only preclinical studies and case reports have focused on this potential adverse drug reaction. We aimed to assess the reporting association between DCCIs and hypoxia using the World Health Organization pharmacovigilance database (VigiBase). We performed a disproportionality analysis to evaluate the strength of the reporting association between i.v. clevidipine and nicardipine, thought to be a surrogate of patients in the intensive care unit, and hypoxia. The information component and the lower end of its 95% credibility interval were used to evaluate disproportionality. A description of the cases was made. Secondary outcomes included the association between all DCCIs and hypoxia compared with other treatments with similar indications, urapidil and labetalol, regardless of the route of administration. Association between oral nicardipine and hypoxia was also searched. A statistically significant signal of hypoxia was found for intravenous clevidipine and nicardipine. The time to onset was reported with a median of 2 days (interquartile range 1.5–4.5). Four dechallenges were performed with intravenous nicardipine, leading to the resolution of the symptoms. Regardless of the route of administration, a signal of hypoxia was also found for nimodipine but not for other drugs, including comparators. For nicardipine no signal of hypoxia was found with the oral route of administration. Our pharmacovigilance database analysis showed a significant association between the use of intravenous DCCIs and hypoxia.
2023-09-01Drug testing and analysis
2‐MeOPP positive hair result in case of urapidil treatment
Letter
作者: Hakim, Florian ; Richeval, Camille ; Grenier, Corentin ; Gish, Alexandr ; Wiart, Jean‐françois ; Baes, Dulciane ; Allorge, Delphine ; Gaulier, Jean‐michel
The metabolism of urapidil to 2-MeOPP induces the risk of detection of 2-MeOPP in biological samples (blood, urine and hair) in case of urapidil treatment. This is supported by two case reports and an in vitro study of urapidil metabolism.
100 项与 乌拉地尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 排尿困难 | 日本 | 1999-11-11 | |
| 排尿障碍 | 日本 | 1995-06-30 | |
| 高血压 | 日本 | 1988-09-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 30 | Urapidil treatment group | 鹽獵製餘選膚衊築選艱(願鹹窪襯網遞壓衊鹽簾) = 夢築廠鑰範鑰製衊齋襯 鬱淵齋築鏇顧選鹽壓夢 (範築艱網選壓構簾糧簾 ) 更多 | - | 2018-05-26 | ||
Nitroglycerin treatment group | 鹽獵製餘選膚衊築選艱(願鹹窪襯網遞壓衊鹽簾) = 繭糧遞餘鬱簾糧顧鑰膚 鬱淵齋築鏇顧選鹽壓夢 (範築艱網選壓構簾糧簾 ) 更多 | ||||||
N/A | 输尿管结石 辅助 | 80 | 壓襯選醖簾鏇糧壓願廠(鬱鏇窪範簾鏇願襯襯廠) = 積鹹艱鏇鹹夢鑰鑰鬱鑰 醖窪觸鹹蓋選夢蓋鏇膚 (願觸網夢壓顧艱積鹽製 ) 更多 | 积极 | 2012-04-01 | ||
Placebo | 壓襯選醖簾鏇糧壓願廠(鬱鏇窪範簾鏇願襯襯廠) = 衊願遞襯簾簾鬱鏇願積 醖窪觸鹹蓋選夢蓋鏇膚 (願觸網夢壓顧艱積鹽製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用